CHICAGO (Reuters) - Gardasil, Merck’s vaccine for preventing cervical cancer in girls and women aged 9 to 26, may offer protection for women up to age 45, the company said on Sunday.In a study of 3,800 women aged 24 to 45, the vaccine prevented 91 percent of cases of persistent infection, minor cervical abnormalities, pre-cancers and genital warts caused by four strains of the sexually transmitted human papillomavirus, or HPV.
